SHR 2005
Alternative Names: SHR-2005Latest Information Update: 01 Oct 2024
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder cancer
Most Recent Events
- 19 Sep 2024 Jiangsu Hengrui Medicine plans a phase I/II trial for Bladder cancer (Inoperable/Unresctable, Combination therapy) in China (SC) (NCT06588179)
- 28 Nov 2023 Phase-I clinical trials in Bladder cancer in China (Intravesicular) (NCT06108492)
- 31 Oct 2023 Shanghai Hengrui Pharmaceutical plans a phase I trial for Bladder cancer in November 2023 (Intravesicular) (NCT06108492)